Thyrotropin (TSH) suppression therapy involves the administration of thyroid hormone in excess of physiological requirements to suppress pituitary TSH secretion in post-DTC patients, which in turn reduces recurrence and metastasis of TSH-dependent carcinomas and decreases carcinoma-associated death. Thyroxine supplementation also corrects hypothyroidism after thyroidectomy and can significantly improve tumor-free survival of patients. Levothyroxine is currently the most commonly used drug for TSH suppression therapy, and its therapeutic dose should be individualized and formulated and adjusted by monitoring of thyroid function. Patients <50 years of age with no previous history of heart disease can reach a full replacement dose as soon as possible; patients ≥50 years of age should have their cardiac status routinely checked before taking levothyroxine, which is generally started at 25-50 μg/d orally once daily and increased by 25 μg every 1 to 2 weeks until the therapeutic goal is reached. The initial treatment usually takes 4-6 weeks, and then the drug dose is adjusted according to the examination results. After the treatment reaches the target, the relevant hormone indexes need to be rechecked every 6-12 months, and total thyroidectomized patients should take the drug for life.